Lantheus Holdings, Inc. (LNTH)
| Market Cap | 1.25B |
| Revenue (ttm) | 339.41M |
| Net Income (ttm) | -13.47M |
| Shares Out | 54.13M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | 83.33 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $18.68 |
| Previous Close | $19.15 |
| Change ($) | -0.47 |
| Change (%) | -2.45% |
| Day's Open | 18.02 |
| Day's Range | 17.27 - 19.15 |
| Day's Volume | 762,494 |
| 52-Week Range | 8.67 - 20.29 |
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted ther...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted ther...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 4:30 p.m. ET on Thursday, Feb...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a glob...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a g...
Is Lantheus Holdings (LNTH) a great pick from the value investor's perspective right now? Read on to know more.
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global l...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a g...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXIN...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI...
Lantheus Holdings, Inc.'s (LNTH) CEO Mary Anne Heino on Q3 2020 Results - Earnings Call Transcript
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 200.00% and -6.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI...
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, m...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, Nov...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXIN...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc.
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc.
Lantheus Holdings, Inc.'s (LNTH) CEO Mary Anne Heino on Q2 2020 Results - Earnings Call Transcript
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc.
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc.
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a...
NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the...
Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q1 2020 Results - Earnings Call Transcript
Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected at $14.03 after the company reported Q1 results.
Lantheus Holding, Inc. (LNTH) CEO Mary Anne Heino on Q4 2019 Results - Earnings Call Transcript
Lantheus Holding Inc. (LNTH) CEO Mary Anne Heino on Q3 2019 Results - Earnings Call Transcript
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 12.00% and 2.11%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the ...
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Micro-cap biotech Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) is advancing strongly following an announcement concerning a buyout deal.
Shares tumble after the company announces a surprise acquisition.
President & CEO of Lantheus Holdings Inc (30-Year Financial, Insider Trades) Mary Anne Heino (insider trades) sold 25,538 shares of LNTH on 09/03/2019 at an average price of $21.21 a share.
Lantheus Holding Inc. (LNTH) CEO Mary Anne Heino on Q2 2019 Results - Earnings Call Transcript
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 0.00% and -3.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) CEO Mary Anne Heino on Q1 2019 Results - Earnings Call Transcript
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 12.00% and -0.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
About LNTH
Lantheus Holdings develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neuro... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 25, 2015 |
| CEO Mary Heino | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol LNTH |
Analyst Forecasts
According to 3 analysts, the average rating for LNTH stock is "Buy." The 12-month stock price forecast is 19.80, which is an increase of 6.00% from the latest price.